CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Swift Biosciences and SeraCare Life Sciences will partner to accelerate development of a novel circulating tumor DNA reference material.
Seraseq ctDNA products are based on patent-pending technology used to make circulating fetal DNA reference materials. Mixtures of DNA containing key somatic mutations at specific allelic frequencies are provided as stabilized material in a proprietary synthetic plasma matrix.
The first ctDNA reference material available for early access is a nine-mutation mixture at varying allele frequencies targeted from five percent down to 0.1 percent. The Seraseq circulating nucleic acid technology is robust and highly amenable to customization, supporting any number of mutations and allele frequencies as quantitated by digital PCR. The combination of design and stabilization technology results in a highly precise and reproducible “ground truth” material suitable for NGS and dPCR assay development and performance monitoring.
Swift Biosciences, 734-330-2568
SeraCare, 508-244-6400